Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Sage Therapeutics Inc.

    NASDAQ: SAGE · Real-Time Price · USD
    6.78
    0.24 (3.67%)
    At close: Jun 05, 2025, 3:59 PM
    6.78
    0.07%
    After-hours: Jun 05, 2025, 04:04 PM EDT

    Sage Therapeutics Statistics

    Share Statistics

    Sage Therapeutics has 62.62M shares outstanding. The number of shares has increased by 2.16% in one year.

    Shares Outstanding

    n/a
    		 62.62M

    Shares Change (YoY)

    n/a
    		 2.16%

    Shares Change (QoQ)

    n/a
    		 0.5%

    Owned by Institutions (%)

    n/a
    		 84.29%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 1,218

    FTD / Avg. Volume

    n/a
    		 0.12%

    Short Selling Information

    The latest short interest is 5.01M, so 8.01% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 5.01M

    Short % of Shares Out

    n/a
    		 8.01%

    Short % of Float

    n/a
    		 8.92%

    Short Ratio (days to cover)

    n/a
    		 5.46

    Valuation Ratios

    The PE ratio is -0.82 and the forward PE ratio is -2.36. Sage Therapeutics's PEG ratio is 0.03.

    PE Ratio

    n/a
    		 -0.82

    Forward PE

    n/a
    		 -2.36

    PS Ratio

    n/a
    		 8

    Forward PS

    n/a
    		 1.9

    PB Ratio

    n/a
    		 0.71

    P/FCF Ratio

    n/a
    		 -1.23

    PEG Ratio

    n/a
    		 0.03
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Sage Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 7.42, with a Debt / Equity ratio of 0.03.

    Current Ratio

    n/a
    		 7.42

    Quick Ratio

    n/a
    		 7.42

    Debt / Equity

    n/a
    		 0.03

    Debt / EBITDA

    n/a
    		 -0.03

    Debt / FCF

    n/a
    		 -0.04

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $116,835.69

    Profits Per Employee

    n/a
    		 $-1,135,031.16

    Employee Count

    n/a
    		 353

    Asset Turnover

    n/a
    		 0.08

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -37.05% in the last 52 weeks. The beta is 0.17, so Sage Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.17

    52-Week Price Change

    n/a
    		 -37.05%

    50-Day Moving Average

    n/a
    		 7.14

    200-Day Moving Average

    n/a
    		 6.93

    Relative Strength Index (RSI)

    n/a
    		 49.22

    Average Volume (20 Days)

    n/a
    		 1,046,303

    Income Statement

    In the last 12 months, Sage Therapeutics had revenue of 41.24M and earned -400.67M in profits. Earnings per share was -6.59.

    Revenue

    n/a
    		 41.24M

    Gross Profit

    n/a
    		 31.8M

    Operating Income

    n/a
    		 -432.37M

    Net Income

    n/a
    		 -400.67M

    EBITDA

    n/a
    		 -409.49M

    EBIT

    n/a
    		 -410.52M

    Earnings Per Share (EPS)

    n/a
    		 -6.59
    Full Income Statement

    Balance Sheet

    The company has 81.02M in cash and 11.84M in debt, giving a net cash position of 69.19M.

    Cash & Cash Equivalents

    n/a
    		 81.02M

    Total Debt

    n/a
    		 11.84M

    Net Cash

    n/a
    		 69.19M

    Retained Earnings

    n/a
    		 -2.97B

    Total Assets

    n/a
    		 469.67M

    Working Capital

    n/a
    		 404.7M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -267.19M and capital expenditures 0, giving a free cash flow of -267.19M.

    Operating Cash Flow

    n/a
    		 -267.19M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -267.19M

    FCF Per Share

    n/a
    		 -4.4
    Full Cash Flow Statement

    Margins

    Gross margin is 77.1%, with operating and profit margins of -1048.35% and -971.48%.

    Gross Margin

    n/a
    		 77.1%

    Operating Margin

    n/a
    		 -1048.35%

    Pretax Margin

    n/a
    		 -971.48%

    Profit Margin

    n/a
    		 -971.48%

    EBITDA Margin

    n/a
    		 -992.86%

    EBIT Margin

    n/a
    		 -1048.35%

    FCF Margin

    n/a
    		 -647.85%

    Dividends & Yields

    SAGE does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for SAGE is $8.5, which is 25.4% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $8.5

    Price Target Difference

    n/a
    		 25.4%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 17
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -6.34

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist